Adaptimmune: The FDA Removed the Temporary Ban on the Trial with NY-ESOS PEAR T-Cell Therapy for Mixoid Round Cell Liposarcoma

The U.S. Food and Drug Administration (FDA) has removed the partial clinical hold it put on Adaptiimmune’s (ADAP) planned study of its NYESO SPEAR™ (Specific Peptide Enhanced Affinity Receptor) T-cell therapy in myxoid round cell liposarcoma (MRCLS).

The move cleared Adaptimmune to start enrolling patients with the MRCLS cancer in a trial of NY‑ESO T-cell therapy partnered with GlaxoSmithKline (GSK)

Adaptimmune will initiate a study in up to 15 MRCLS patients. Patient screening is expected to begin in 4Q 2016. Results from this study . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.